Telomir Pharmaceuticals (TELO) director resets 25K stock options terms
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Telomir Pharmaceuticals, Inc. director Matthew Paul Del Giudice reported a restructuring of his stock options with no net change in option count. He agreed to cancel 25,000 fully exercisable incentive stock options for common stock with a $5.02 exercise price and a August 27, 2034 expiration, as a disposition back to the issuer.
In exchange, he received a new grant of 25,000 incentive stock options for common stock with a lower exercise price of $1.30 per share and a May 21, 2036 expiration. Following these transactions, he holds 25,000 stock options directly, and no common shares were bought or sold in the market.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Del Giudice Matthew Paul
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Incentive Stock Options (right to buy) | 25,000 | $0.00 | -- |
| Disposition | Incentive Stock Options (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Incentive Stock Options (right to buy) — 25,000 shares (Direct, null)
Footnotes (1)
- The options are fully exercisable. The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price.
Key Figures
Options cancelled: 25,000 options
Cancelled option exercise price: $5.02/share
Cancelled option expiration: August 27, 2034
+4 more
7 metrics
Options cancelled
25,000 options
Incentive stock options disposed to issuer on May 21, 2026
Cancelled option exercise price
$5.02/share
Exercise price of option grant dated August 27, 2024
Cancelled option expiration
August 27, 2034
Original expiration of disposed incentive stock options
New options granted
25,000 options
Incentive stock options granted on May 21, 2026
New option exercise price
$1.30/share
Exercise price of newly granted incentive stock options
New option expiration
May 21, 2036
Expiration date of newly granted incentive stock options
Options held after transactions
25,000 options
Total derivative holdings following reported Form 4 transactions
Key Terms
Incentive Stock Options, Disposition to issuer, Grant, award, or other acquisition, exercise price, +1 more
5 terms
Incentive Stock Options financial
"Incentive Stock Options (right to buy)"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
Disposition to issuer financial
"transaction_code_description: Disposition to issuer"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 5.0200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-05-21T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Telomir Pharmaceuticals (TELO) director report in this Form 4?
The director reported canceling 25,000 incentive stock options and receiving a new grant of 25,000 options. The change updates exercise price and expiration but leaves his total option count unchanged at 25,000, with no open-market share purchases or sales.
How many Telomir (TELO) stock options were cancelled and re-granted?
He cancelled 25,000 incentive stock options and received a new grant of 25,000 options. The one-for-one exchange keeps his derivative holdings at 25,000 options, changing only the terms, not the number of options or common shares outstanding.
What are the exercise prices of the Telomir (TELO) options in this Form 4?
The cancelled incentive stock options had a conversion or exercise price of $5.02 per share. The new incentive stock options were granted with a lower exercise price of $1.30 per share, improving the economic terms of his compensation-linked option position.
What are the expiration dates of the Telomir (TELO) stock options mentioned?
The cancelled option grant was scheduled to expire on August 27, 2034. The newly granted 25,000 incentive stock options expire later, on May 21, 2036, extending the director’s time window to exercise these compensation-related options for common stock.
How did this Telomir (TELO) Form 4 affect the director’s total option holdings?
After cancelling and re-granting 25,000 incentive stock options, the director’s total reported option holdings stand at 25,000. The transactions adjust exercise price and expiration date but do not increase or decrease the aggregate number of options he holds.